impassion130: addressing immune-related aes in tnbc management
Published 4 years ago • 21 plays • Length 2:44Download video MP4
Download video MP3
Similar videos
-
4:47
tnbc: updated efficacy results from impassion130
-
2:33
applying impassion130 data to tnbc management
-
7:19
impassion130 trial: os updates in metastatic tnbc
-
8:42
chemoimmunotherapy in tnbc: the impassion130 trial
-
2:51
impassion130: design and preliminary efficacy
-
4:33
i-o in tnbc: impassion130 trial design and results
-
3:33
aromatase inhibitors for breast cancer
-
4:48
breast cancer breakthroughs: the importance of esr1 mutations in metastatic breast cancer
-
13:38
breast cancer recurrence prevention - an illustrative tutorial from oster oncology
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
2:30
impassion130: immunotherapy for tnbc
-
4:11
immunotherapy for tnbc: impassion130 & keynote-355
-
4:27
the impassion130 study in metastatic tnbc
-
0:59
impassion130 data demonstrate clinical benefit for immunotherapy in metastatic tnbc
-
1:46
dr. schmid discusses the findings of impassion130 in tnbc
-
2:07
tnbc: using checkpoint inhibitors alone or with chemotherapy
-
21:36
treatment planning for triple negative breast cancer | 2022 evolution conference
-
1:16
the impassion130 trial in metastatic triple-negative breast cancer
-
5:59
impassion130: atezolizumab and nab-paclitaxel in triple-negative breast cancer
-
31:24
harnessing the immune system in the treatment of triple-negative breast cancer
-
6:54
impassion130 trial data on pd-l1 tumors in tnbc
-
6:33
case 3: results of the impassion130 trial in metastatic breast cancer